Join Now

Help change the future of PKU

Complete the form below and we will contact you as the site is updated. Increasing our knowledge of the neurological impact of phenylketonuria (PKU)—and its connection to clinical outcomes—may guide new approaches in management.1

We look forward to being a reliable source of relevant information about the impact of elevated phenylalanine (Phe) in PKU, as well as approaches to management and support tools.

Indicates required field

Do you conduct research on PKU?

This information is intended for healthcare professionals. By completing and submitting this form, you certify that you are a licensed healthcare professional, and you are indicating that you would like to receive more information related to PKU.

By submitting this completed form, you agree to allow BioMarin and third parties acting on behalf of BioMarin to collect your information and to send you e-mails regarding updates related to PKU which will be stored in the United States.

BioMarin will not sell, rent, or otherwise distribute your information outside of BioMarin and related third parties. BioMarin will only use the information you enter in accordance with its Privacy Policy.

Reference:

  1. Vockley J, Andersson HC, Antshel KM, et al; for American College of Medical Genetics and Genomics Therapeutic Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-190. doi:10.1038/gim.2013.157.